-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

613.O3.6 613. Acute Myeloid Leukemias: Clinical and Epidemiological: Genomic Determinants of Prognosis in Patients with Acute Myeloid Leukemia

Symposia: Acute Myeloid Leukemias: Clinical and Epidemiological Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Acute Myeloid Malignancies, AML, Fundamental Science, Translational Research, Clinical Practice (Health Services and Quality), epidemiology, Clinical Research, genomics, health outcomes research, Diversity, Equity, and Inclusion (DEI) , Chronic Myeloid Malignancies, Diseases, Therapies, Myeloid Malignancies, Biological Processes, Human
Sunday, December 11, 2022: 4:30 PM-6:00 PM
353-355 (Ernest N. Morial Convention Center)
Moderators:
Alice S. Mims, MD, The Ohio State University Comprehensive Cancer Center and Gautam Borthakur, MD, University of Texas MD Anderson Cancer Center, Department of Leukemia
Disclosures:
Mims: Servier: Membership on an entity's Board of Directors or advisory committees; Syndax: Membership on an entity's Board of Directors or advisory committees; Astellas: Membership on an entity's Board of Directors or advisory committees; AbbVie: Membership on an entity's Board of Directors or advisory committees; Daiichi Sankyo: Other: Data Safety and Monitoring Board; BMS: Membership on an entity's Board of Directors or advisory committees; Ryvu: Membership on an entity's Board of Directors or advisory committees; Jazz Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees, Other: Data Safety and Monitoring Board; Zentalis: Membership on an entity's Board of Directors or advisory committees; Genentech: Membership on an entity's Board of Directors or advisory committees.
Studies in this section describe the impact of specific genomic aberrations on prognosis in patients with acute myeloid leukemia.
4:30 PM

Shuai-Shuai Ge1,2*, Xiangdong Shen1,2*, Tianmei Wu3*, Jiahui Du4*, Haiping Dai1,2*, Qiaocheng Qiu1,2*, Songbai Liu, PhD4*, Depei Wu1,2 and Shengli Xue1,2*

1National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
2Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
3Gusu District Maternal and Child Health Center, Suzhou, China
4Suzhou Key Laboratory of Medical Biotechnology, Suzhou Vocational Health College, Suzhou, China

4:45 PM

Jayastu Senapati, MD, MBBS, DM1*, Nicholas Short, MD2, Abhishek Maiti, MBBS1, Hussein A Abbas, MD, PhD1, Naval Daver, MD1, Naveen Pemmaraju, MD1, Sherry A. Pierce, BSN, BA1*, Kelly S. Chien, MD1, Koji Sasaki, MD1, Danielle Hammond, MD1, Gautam Borthakur, MD1, Farhad Ravandi, MD1, Hagop Kantarjian, MD3 and Courtney D. DiNardo, MD, MSCE1

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
3Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

5:00 PM

Michael J. Hochman, MD1, Megan Othus, PhD2, Robert P. Hasserjian, MD3, Alexander J. Ambinder, MD, MPH1, Andrew M. Brunner, MD4, Mary-Elizabeth M. Percival, MD5,6, Christopher S. Hourigan, MD7, Ronan Swords, MD PhD8, Amy E. DeZern, MD1, Elihu H. Estey, M.D.5,6 and Judith E. Karp, MD1

1Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
2Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA
3Department of Pathology, Massachusetts General Hospital, Boston, MA
4Mass General Cancer Center, Massachusetts General Hospital, Boston, MA
5Division of Hematology, Department of Medicine, University of Washington, Seattle, WA
6Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
7Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
8Knight Cancer Institute, Oregon Health & Science University, Portland

5:15 PM

Abdul Moiz Khan, MD1, Sushmitha Nanja Reddy, MBBS2*, Mai M M Aly, MD3,4*, Vikram Dhillon, DO2*, Ali Al Sbihi, MD2*, Tariq Kewan, MD4*, Waled Bahaj, MD4, Carmelo Gurnari, MD4,5, Bayan Al-Share, MD6*, Gregory Dyson1*, Valeria Visconte, PhD4 and Suresh Kumar Balasubramanian, MD4,7

1Department of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, MI
2Department of Internal Medicine, Wayne State University, Detroit, MI
3Assiut University Hospital, Clinical Hematology Unit, Internal Medicine Department,, Assiut, Egypt
4Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
5Department of Biomedicine and Prevention, Ph.D. in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Rome, Italy
6Monument Health Cancer Care Institute, Rapid City, SD
7Department of Oncology, Wayne State University/ Karmanos Cancer Institute, Detroit, MI

5:30 PM

Talha Badar, MD1, Ehab L. Atallah, MD2, Rory M. Shallis, MD3, Antoine N. Saliba, MD4, Maximilian F. Stahl, MD5, Jan Philipp Bewersdorf, MD6, Justin Grenet, MD7, Anand Ashwin Patel, MD8, Yasmin Abaza, MD9, Guru Subramanian Guru Murthy, MBBS10, Adam S Duvall, MD11, Madelyn Burkart, MD12, Neil Palmisiano, MD, MS13, Michal Jakub Kubiak, MD14, Vamsi K. Kota, MD15, Shira Dinner, MD9, Aaron D Goldberg, MD, PhD16 and Mark R. Litzow, MD4

1Division of Hematology and Oncology, Mayo Clinic Florida, Jacksonville, FL
2Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI
3Yale University School of Medicine, New Haven, CT
4Division of Hematology, Mayo Clinic, Rochester, MN
5Department of Medical Oncology, Dana-Farber Institute, Boston, MA
6Department of Internal Medicine, YALE UNIVERSITY SCHOOL OF MEDICINE, New Haven, CT
7New York Presbyterian/Weill-Cornell Medical Center, New York, NY
8Department of Medicine, Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL
9Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
10Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
11Department of Medicine, University of Chicago, Chicago, IL
12Department of Medicine, Division of Hematology/Oncology and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Northwestern University Feinberg School of Medicine, Chicago, IL
13Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA
14Augusta University, Augusta, GA
15Division of Hematology/Oncology, Georgia Cancer Center at Augusta University, Augusta, GA
16Memorial Sloan Kettering Cancer Center, New York, NY

5:45 PM

Abdul Rahman Al Armashi, MD1*, Anas Al Zubaidi, MD2*, Dina Elantably, MD3*, Jiasheng Wang, MD1 and Akram Alkrekshi, MD4*

1Department of Hematology and Oncology, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH
2Johns Hopkins University, Baltimore, MD
3Department of Internal Medicine, Case Western Reserve University MetroHealth Medical Center, Cleveland, OH
4Department of Internal Medicine, Case Western Reserve University MetroHealth Medical Center, Westlake, OH

*signifies non-member of ASH